Clinical trials recently hit the headlines in relation to industry transparency of the data collected during them. As you know, we have been quite vocal on this specific debate.
There are, however, other important and often overlooked points to be made on this topic, in particular in relation to ensuring the EU remains an attractive place for conducting clinical trials, and delivers faster access for patients to new medicines.
Lilly conducts clinical research in over 55 countries worldwide. Clinical trials provide a pathway for pharmaceutical companies like ours to demonstrate the efficacy and safety of our new healthcare solutions. They are a vital part of how medicines end up with those who need them. But several factors hold the industry back in delivering on the full potential from the clinical trials process.
An influential UK Parliamentary committee recently highlighted European barriers to conducting clinical trials. Rules governing clinical trials in Europe are currently being revised to improve patient safety by simplifying and harmonising requirements for clinical trials, and enhancing the coordination of clinical trials in the EU. They are also looking to increase the competitiveness of European clinical research amid concerns that Europe was becoming an unattractive place to conduct large-scale clinical trials.
Even with better conditions for conducting clinical trials, a potential remaining threat are general misconceptions of what clinical trials entail by those needed to take part. This risk has the potential to hold back progress of many solutions to critical unmet medical needs.
At next week Alzheimer's Europe 23rd Annual Conference Lilly will be presenting new insights from a global survey of public, patients and caregivers on the subject of patient participation in cancer care clinical trials. We will report further on the findings next week, but slow recruitment for clinical trials, especially for areas such as Alzheimer's disease, raises an important dilemma that must be addressed.
Greater education of clinical trials is critical in overcoming these particular barriers. During the conference, we will also be exploring possible solutions for patient advocacy groups to play an important role in this process. We look forward to reporting on that, too.
On the final day of World Alzheimer's month, we believe it is important to shine the spotlight on such issues, especially as they relate to diseases affecting so many. We look forward to continuing contributing to these debates over the coming week with key healthcare partners and discovering solutions to address the concerns.